Naproxen (brand names: Aleve, Naprosyn, and many others) is a nonsteroidal anti-inflammatory drug (NSAID) of the propionic acid class (the same class as ibuprofen) that relieves pain, fever, swelling, and stiffness. It is a nonselective COX inhibitor, usually sold as the sodium salt. It is available in both an immediate release and extended release formulation. Naproxen is generally safe to use in breastfeeding mothers.
Side Effects[edit | edit source]
Using nonsteroidal anti-inflammatory precautions is recommended to avoid gastrointestinal side effects. Hepatic and renal dysfunction may occur, and peripheral edema.Central nervous system side effects include "dizziness, headaches, drowsiness and evidence of hypersensitives." 
More commonly reported ones are:
- Gastrointestinal side-effects including bleeding.
More commonly reported ones in children are:
Less commonly reported ones are:
Evidence[edit | edit source]
Dose[edit | edit source]
A dose of 250mg is suggested, as needed, up to 3 times a day, according to by the Canadian Consensus Criteria.
Learn more[edit | edit source]
See also[edit | edit source]
References[edit | edit source]
- Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, A C Peter; Sherkey, Jeffrey A.; van de Sande, Marjorie I. (2003), "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols" (PDF), Journal of Chronic Fatigue Syndrome, 11 (2): 53-55, doi:10.1300/J092v11n01_02, ISBN 9780789022073
Adverse reaction - Any unintended or unwanted response to the treatment under investigation in a clinical trial.
Canadian consensus criteria (CCC) - A set of diagnostic criteria used to diagnose ME/CFS, developed by a group of practicing ME/CFS clinicians in 2003. The CCC is often considered to be the most complex criteria, but possibly the most accurate, with the lowest number of patients meeting the criteria. Led to the development of the International Consensus Criteria (ICC) in 2011.